Royalty Pharma Lifts 2026 Outlook After Robust Q2 Royalty Receipts

summarizeSummary

Royalty Pharma posted Q2 2026 Portfolio Receipts of $773 million, up 6%, and raised full-year guidance to $3.4–$3.5 billion. Royalty Receipts grew 14%, operating cash flow doubled, and the company deployed $349 million in new royalty acquisitions.

check_boxKey Events · Earnings and Guidance · RPRX

• Q2 Portfolio Receipts Rise 6%

  Portfolio Receipts reached $773 million, driven by 14% growth in Royalty Receipts to $768 million, led by Tremfya, Voranigo, Imdelltra, and Evrysdi.

• Full-Year Guidance Raised

  2026 Portfolio Receipts guidance increased to $3,400–$3,500 million (from $3,325–$3,450 million), implying Royalty Receipts growth of 7–10%.

• Operating Cash Flow Doubles

  Net cash provided by operating activities was $728 million, up 100% year-over-year, reflecting strong cash generation from the royalty portfolio.

• Capital Deployment Tops $1 Billion YTD

  Capital Deployment was $349 million in Q2 and $877 million in H1 2026, including the $125 million upfront payment for the cliramitug royalty and development-stage funding.

auto_awesomeAnalysis · RPRX · Life Sciences

A strong second quarter saw Royalty Receipts climb 14%, fueled by key products such as Tremfya and Voranigo. For the second time this year, the company raised its full-year Portfolio Receipts guidance, now targeting $3.4–$3.5 billion. Operating cash flow doubled to $728 million, and the balance sheet remains solid with $812 million in cash following the repayment of a $380 million term loan. The pipeline continues to advance, highlighted by the cliramitug royalty acquisition and multiple regulatory milestones across the portfolio. This earnings report underscores the company's ability to generate consistent, compounding growth from its diversified royalty portfolio.